非處方藥市場－全球產業規模、佔有率、趨勢、機會及預測（按產品、劑型、地區和競爭細分，2020-2030 年）

2024 年全球非處方藥 (OTC) 市場價值為 102.5 億美元，預計到 2030 年將達到 154.8 億美元，預測期內的複合年成長率為 7.31%。 OTC 藥物是一種方便且經濟有效的選擇，無需處方即可治療頭痛、過敏、感冒、消化問題和輕微皮膚刺激等常見健康狀況。不斷上漲的醫療成本和日益成長的自我照顧傾向是市場成長的主要推動因素。消費者正在尋求可獲得的治療替代方案，以減少對專業諮詢的需求，這促使製藥公司擴大其 OTC 產品組合，並投資於創新的給藥方式和消費者意識計劃。然而，市場擴張受到與不當使用相關的挑戰的阻礙，包括過度使用的風險和自我藥療可能引起的併發症，尤其是在藥劑師監督或監管執法有限的地區。

關鍵市場促進因素

醫療保健產業的成長

主要市場挑戰

濫用和自我用藥的風險

主要市場趨勢

利基OTC市場的成長

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：COVID-19 對全球非處方藥 (OTC) 市場的影響

第5章：全球非處方藥（OTC）市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依產品（咳嗽、感冒和流感、維生素、礦物質和補充劑 (VMS)、鎮痛藥、胃腸道產品、皮膚病學產品、其他）
  • 按劑型（片劑、膠囊、液體和溶液、乳膏/乳液/軟膏、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美非處方藥（OTC）市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第7章：歐洲非處方藥（OTC）市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太非處方藥（OTC）市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲

第9章：南美非處方藥（OTC）市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東和非洲非處方藥（OTC）市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如有）
• 最新動態

第13章：干擾：衝突、流行病與貿易壁壘

第 14 章：全球非處方藥 (OTC) 市場：SWOT 分析

第 15 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 16 章：競爭格局

• Sanofi SA
• Pfizer Inc.
• GlaxoSmithKline plc
• Perrigo Company plc
• Reckitt Benckiser Group PLC
• Takeda Pharmaceutical Company Ltd
• Boehringer Ingelheim International GmbH
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Glenmark Pharmaceuticals Ltd.

第 17 章：策略建議

第18章調查會社について,免責事項

The Global Over the Counter (OTC) Drugs Market was valued at USD 10.25 Billion in 2024 and is projected to reach USD 15.48 Billion by 2030, registering a CAGR of 7.31% during the forecast period. OTC drugs are a convenient and cost-effective option for managing common health conditions such as headaches, allergies, colds, digestive issues, and minor skin irritations without requiring a prescription. Increasing healthcare costs and a growing inclination toward self-care are major contributors to market growth. Consumers are seeking accessible treatment alternatives that reduce the need for professional consultations, prompting pharmaceutical companies to expand their OTC portfolios and invest in innovative delivery forms and consumer awareness initiatives. However, the market's expansion is tempered by challenges related to improper use, including risks of overuse and potential complications due to self-medication, particularly in regions with limited pharmacist oversight or regulatory enforcement.

Key Market Drivers

Growth in Healthcare Industry

The growing global healthcare industry significantly supports the expansion of the OTC drugs market. Generating over USD 4 trillion annually, the healthcare sector includes highly profitable domains such as pharmaceuticals and biotechnology, which contribute nearly USD 850 billion, and medical technology and diagnostics, accounting for more than USD 400 billion. As healthcare systems become more focused on patient-centered care and cost efficiency, consumers are increasingly turning to OTC medications to manage routine health issues independently. This shift reflects a broader movement toward preventative care, convenience, and greater consumer empowerment, which is driving demand for safe, effective, and readily available OTC treatment options.

Key Market Challenges

Risk of Misuse and Self-Medication

A major concern in the OTC drugs market is the potential for misuse and self-medication. The ease of access to OTC products, while beneficial for minor ailments, can result in unintended health risks when these products are used without adequate medical guidance. Improper dosing, extended use beyond recommended guidelines, or reliance on OTC drugs to manage symptoms of more serious conditions can lead to adverse outcomes. Misuse is particularly common with medications such as analgesics, antacids, and antihistamines, which consumers may not fully understand in terms of contraindications or possible drug interactions. This lack of oversight increases the risk of masking underlying illnesses or exacerbating health issues due to incorrect use.

Key Market Trends

Growth of Niche OTC Segments

The market is witnessing rising interest in niche OTC segments tailored to specific consumer needs and health conditions. As awareness of individual health concerns grows, consumers are seeking more targeted non-prescription solutions that go beyond general-purpose remedies. Categories such as sleep aids, digestive health supplements, women's health products, pediatric treatments, and plant-based options are gaining momentum. These offerings respond to a rising preference for self-managed wellness and preventive care. For instance, sleep aids typically rely on antihistamines like diphenhydramine and doxylamine to reduce wakefulness. Growing attention to conditions such as insomnia, digestive discomfort, and seasonal allergies has fueled demand for customized OTC solutions, encouraging companies to diversify their offerings and explore functional innovations aligned with consumer wellness trends.

Key Market Players

• Sanofi SA
• Pfizer Inc.
• GlaxoSmithKline plc
• Perrigo Company plc
• Reckitt Benckiser Group PLC
• Takeda Pharmaceutical Company Ltd
• Boehringer Ingelheim International GmbH
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Glenmark Pharmaceuticals Ltd.

Report Scope

In this report, the Global Over the Counter (OTC) Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Over the Counter (OTC) Drugs Market, By Product:

• Cough
• Cold & Flu
• Vitamins, Mineral, & Supplements (VMS)
• Analgesics
• Gastrointestinal Products
• Dermatology Products
• Others

Over the Counter (OTC) Drugs Market, By Dosage Form:

• Tablets
• Capsules
• Liquids & Solutions
• Cream/Lotion/Ointments
• Others

Over the Counter (OTC) Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Over the Counter (OTC) Drugs Market.

Available Customizations

Global Over the Counter (OTC) Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Over the Counter (OTC) Drugs Market

5. Global Over the Counter (OTC) Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Cough, Cold & Flu, Vitamins, Mineral, & Supplements (VMS), Analgesics, Gastrointestinal Products, Dermatology Products, Others)
  • 5.2.2. By Dosage Form (Tablets, Capsules, Liquids & Solutions, Cream/Lotion/Ointments, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Over the Counter (OTC) Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Dosage Form
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Over the Counter (OTC) Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Dosage Form
  • 6.3.2. Mexico Over the Counter (OTC) Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Dosage Form
  • 6.3.3. Canada Over the Counter (OTC) Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Dosage Form

7. Europe Over the Counter (OTC) Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Dosage Form
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Over the Counter (OTC) Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Dosage Form
  • 7.3.2. Germany Over the Counter (OTC) Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Dosage Form
  • 7.3.3. United Kingdom Over the Counter (OTC) Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Dosage Form
  • 7.3.4. Italy Over the Counter (OTC) Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Dosage Form
  • 7.3.5. Spain Over the Counter (OTC) Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Dosage Form

8. Asia Pacific Over the Counter (OTC) Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Dosage Form
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Over the Counter (OTC) Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Dosage Form
  • 8.3.2. India Over the Counter (OTC) Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Dosage Form
  • 8.3.3. South Korea Over the Counter (OTC) Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Dosage Form
  • 8.3.4. Japan Over the Counter (OTC) Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Dosage Form
  • 8.3.5. Australia Over the Counter (OTC) Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Dosage Form

9. South America Over the Counter (OTC) Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Dosage Form
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Over the Counter (OTC) Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Dosage Form
  • 9.3.2. Argentina Over the Counter (OTC) Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Dosage Form
  • 9.3.3. Colombia Over the Counter (OTC) Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Dosage Form

10. Middle East and Africa Over the Counter (OTC) Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Dosage Form
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Over the Counter (OTC) Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Dosage Form
  • 10.3.2. Saudi Arabia Over the Counter (OTC) Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Dosage Form
  • 10.3.3. UAE Over the Counter (OTC) Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Dosage Form

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Over the Counter (OTC) Drugs Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. Sanofi SA
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Pfizer Inc.
• 16.3. GlaxoSmithKline plc
• 16.4. Perrigo Company plc
• 16.5. Reckitt Benckiser Group PLC
• 16.6. Takeda Pharmaceutical Company Ltd
• 16.7. Boehringer Ingelheim International GmbH
• 16.8. Sun Pharmaceutical Industries Ltd.
• 16.9. Teva Pharmaceutical Industries Ltd.
• 16.10. Glenmark Pharmaceuticals Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer